S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:RVLP

RVL Pharmaceuticals (RVLP) Stock Forecast, Price & News

$0.85
+0.02 (+1.84%)
(As of 05:11 PM ET)
Compare
Today's Range
$0.81
$0.87
50-Day Range
$0.77
$1.17
52-Week Range
$0.72
$2.99
Volume
32,340 shs
Average Volume
58,078 shs
Market Capitalization
$84.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.83

RVL Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
234.2% Upside
$2.83 Price Target
Short Interest
Healthy
0.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.24mentions of RVL Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.39) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

352nd out of 981 stocks

Pharmaceutical Preparations Industry

163rd out of 475 stocks


RVLP stock logo

About RVL Pharmaceuticals (NASDAQ:RVLP) Stock

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
RVL Pharmaceuticals (NASDAQ:RVLP) Price Target Cut to $4.00
RVLP: First Quarter Results
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Q1 2023 RVL Pharmaceuticals PLC Earnings Call
RVLP: Selected for NewBeauty Award
RVL Pharmaceuticals (NASDAQ:RVLP) Shares Down 4.3%
RVL Pharmaceuticals plc
See More Headlines

RVLP Price History

RVLP Company Calendar

Last Earnings
3/20/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVLP
Fax
N/A
Employees
156
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.83
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+225.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-51,690,000.00
Net Margins
-152.21%
Pretax Margin
-151.90%

Debt

Sales & Book Value

Annual Sales
$49.72 million
Book Value
$0.51 per share

Miscellaneous

Free Float
94,084,000
Market Cap
$86.43 million
Optionable
Optionable
Beta
1.21

Key Executives

  • Brian A. Markison
    Chairman, Chief Executive & Financial Officer
  • James Schaub
    Chief Operating Officer & Executive Vice President
  • Sergio Alegre
    Vice President-Global Compliance
  • Michael J. Depetris
    Chief Accounting Officer
  • Jarret Miller
    Executive Vice President-Human Resources













RVLP Stock - Frequently Asked Questions

Should I buy or sell RVL Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVLP shares.
View RVLP analyst ratings
or view top-rated stocks.

What is RVL Pharmaceuticals' stock price forecast for 2023?

3 analysts have issued 1 year target prices for RVL Pharmaceuticals' stock. Their RVLP share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.83 in the next twelve months. This suggests a possible upside of 225.7% from the stock's current price.
View analysts price targets for RVLP
or view top-rated stocks among Wall Street analysts.

How have RVLP shares performed in 2023?

RVL Pharmaceuticals' stock was trading at $1.12 at the beginning of 2023. Since then, RVLP shares have decreased by 22.3% and is now trading at $0.87.
View the best growth stocks for 2023 here
.

Are investors shorting RVL Pharmaceuticals?

RVL Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 65,700 shares, a decline of 24.7% from the April 30th total of 87,300 shares. Based on an average daily trading volume, of 69,300 shares, the short-interest ratio is presently 0.9 days. Approximately 0.1% of the company's stock are short sold.
View RVL Pharmaceuticals' Short Interest
.

When is RVL Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RVLP earnings forecast
.

How were RVL Pharmaceuticals' earnings last quarter?

RVL Pharmaceuticals plc (NASDAQ:RVLP) announced its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.03. The company had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 111.27% and a negative net margin of 152.21%. During the same period in the previous year, the business earned ($0.26) EPS.

What is RVL Pharmaceuticals' stock symbol?

RVL Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVLP."

Who are RVL Pharmaceuticals' major shareholders?

RVL Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (1.26%), Renaissance Technologies LLC (0.70%), Scoggin Management LP (0.50%), Titleist Asset Management LLC (0.11%), Insight Advisors LLC PA (0.08%) and Dimensional Fund Advisors LP (0.07%).

How do I buy shares of RVL Pharmaceuticals?

Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RVL Pharmaceuticals' stock price today?

One share of RVLP stock can currently be purchased for approximately $0.87.

How much money does RVL Pharmaceuticals make?

RVL Pharmaceuticals (NASDAQ:RVLP) has a market capitalization of $86.43 million and generates $49.72 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does RVL Pharmaceuticals have?

The company employs 156 workers across the globe.

How can I contact RVL Pharmaceuticals?

RVL Pharmaceuticals' mailing address is 400 Crossing Blvd, Bridgewater, New Jersey 08807-2863. The official website for the company is www.osmotica.com. The company can be reached via phone at (908) 809-1300 or via email at lwilson@insitecony.com.

This page (NASDAQ:RVLP) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -